» Articles » PMID: 25285958

Short Hairpin RNA Library-based Functional Screening Identified Ribosomal Protein L31 That Modulates Prostate Cancer Cell Growth Via P53 Pathway

Overview
Journal PLoS One
Date 2014 Oct 7
PMID 25285958
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen receptor is a primary transcription factor involved in the proliferation of prostate cancer cells. Thus, hormone therapy using antiandrogens, such as bicalutamide, is a first-line treatment for the disease. Although hormone therapy initially reduces the tumor burden, many patients eventually relapse, developing tumors with acquired endocrine resistance. Elucidation of the molecular mechanisms underlying endocrine resistance is therefore a fundamental issue for the understanding and development of alternative therapeutics for advanced prostate cancer. In the present study, we performed short hairpin RNA (shRNA)-mediated functional screening to identify genes involved in bicalutamide-mediated effects on LNCaP prostate cancer cells. Among such candidate genes selected by screening using volcano plot analysis, ribosomal protein L31 (RPL31) was found to be essential for cell proliferation and cell-cycle progression in bicalutamide-resistant LNCaP (BicR) cells, based on small interfering RNA (siRNA)-mediated knockdown experiments. Of note, RPL31 mRNA is more abundantly expressed in BicR cells than in parental LNCaP cells, and clinical data from ONCOMINE and The Cancer Genome Altas showed that RPL31 is overexpressed in prostate carcinomas compared with benign prostate tissues. Intriguingly, protein levels of the tumor suppressor p53 and its targets, p21 and MDM2, were increased in LNCaP and BicR cells treated with RPL31 siRNA. We observed decreased degradation of p53 protein after RPL31 knockdown. Moreover, the suppression of growth and cell cycle upon RPL31 knockdown was partially recovered with p53 siRNA treatment. These results suggest that RPL31 is involved in bicalutamide-resistant growth of prostate cancer cells. The shRNA-mediated functional screen in this study provides new insight into the molecular mechanisms and therapeutic targets of advanced prostate cancer.

Citing Articles

Bioinformatics-based analysis of the dialog between COVID-19 and RSA.

Bi Y, Li T, Zhang S, Yang Y, Dong M Heliyon. 2024; 10(9):e30371.

PMID: 38737245 PMC: 11088317. DOI: 10.1016/j.heliyon.2024.e30371.


Identification of genes related to ribosomal proteins in colorectal cancer: exploring their potential as biomarkers, prognostic indicators, and therapeutic targets.

Salehinia N, Mohammad Al-Mosawi A, Al-Moussawi D, Sadeghi E, Zamani A, Mahdevar M Mol Biol Rep. 2024; 51(1):576.

PMID: 38664314 DOI: 10.1007/s11033-024-09522-5.


SYT7 (synaptotagmin 7) promotes cervical squamous cell carcinoma.

Huang J, Xu W, Huang Q, Chen E, Chen J Heliyon. 2024; 10(3):e24806.

PMID: 38314285 PMC: 10837561. DOI: 10.1016/j.heliyon.2024.e24806.


Two-Dimensional Polyacrylamide Gel Electrophoresis Coupled with Nanoliquid Chromatography-Tandem Mass Spectrometry-Based Identification of Differentially Expressed Proteins and Tumorigenic Pathways in the MCF7 Breast Cancer Cell Line Transfected for....

Jayathirtha M, Jayaweera T, Whitham D, Petre B, Neagu A, Darie C Int J Mol Sci. 2023; 24(19).

PMID: 37834160 PMC: 10572688. DOI: 10.3390/ijms241914714.


PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation.

Li X, Li X, Hu Y, Liu O, Wang Y, Li S BMC Cancer. 2023; 23(1):573.

PMID: 37349676 PMC: 10286491. DOI: 10.1186/s12885-023-11017-8.


References
1.
Compagno D, Merle C, Morin A, Gilbert C, Mathieu J, Bozec A . SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One. 2007; 2(10):e1006. PMC: 1994591. DOI: 10.1371/journal.pone.0001006. View

2.
Okamoto K, Taya Y, Nakagama H . Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett. 2009; 583(17):2710-4. DOI: 10.1016/j.febslet.2009.07.021. View

3.
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J . Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997; 57(2):314-9. View

4.
Gregory C, Johnson Jr R, Mohler J, French F, Wilson E . Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001; 61(7):2892-8. View

5.
Dahlman K, Parker J, Shamu T, Hieronymus H, Chapinski C, Carver B . Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One. 2012; 7(4):e34414. PMC: 3324507. DOI: 10.1371/journal.pone.0034414. View